Enliven sticks to year-end ENABLE-2 start after FDA alignment on CML trial designNov 6Regulatory decisionEnliven TherapeuticsUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
BMS posts RELATIVITY-106 liver cancer results; files two new Phase 1/2 trialsOct 16Weekly roundup, 4 itemsBioNTech SEBristol Myers SquibbUpdated
Sign inSign in